These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8378706)

  • 1. Clinical pathologic alterations associated with subcutaneous administration of recombinant human interleukin-4 to cynomolgus monkeys.
    Gossett KA; Barbolt TA; Cornacoff JB; Zelinger DJ; Dean JH
    Toxicol Pathol; 1993; 21(1):46-53. PubMed ID: 8378706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of recombinant human interleukin-4.
    Cornacoff JB; Gossett KA; Barbolt TA; Dean JH
    Toxicol Lett; 1992 Dec; 64-65 Spec No():299-310. PubMed ID: 1471185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histomorphologic observations for cynomolgus monkeys after subchronic subcutaneous injection of recombinant human interleukin-4.
    Barbolt TA; Gossett KA; Cornacoff JB
    Toxicol Pathol; 1991; 19(3):251-7. PubMed ID: 1780642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri).
    Sarmiento UM; Riley JH; Knaack PA; Lipman JM; Becker JM; Gately MK; Chizzonite R; Anderson TD
    Lab Invest; 1994 Dec; 71(6):862-73. PubMed ID: 7807968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombopoietic activity of recombinant human interleukin-11 in nonhuman primates with ACNU-induced thrombocytopenia.
    Saitoh M; Taguchi K; Yasuda S; Kikumori M; Nishimori T; Suda M; Okamiya H; Usuda S; Miyata K
    J Interferon Cytokine Res; 2000 Jun; 20(6):539-45. PubMed ID: 10888110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates.
    Schlerman FJ; Bree AG; Kaviani MD; Nagle SL; Donnelly LH; Mason LE; Schaub RG; Grupp SA; Goldman SJ
    Stem Cells; 1996 Sep; 14(5):517-32. PubMed ID: 8888493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety evaluation of recombinant human interleukin-4. II. Clinical studies.
    Leach MW; Rybak ME; Rosenblum IY
    Clin Immunol Immunopathol; 1997 Apr; 83(1):12-4. PubMed ID: 9073527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical safety of recombinant human interleukin-18.
    Herzyk DJ; Bugelski PJ; Hart TK; Wier PJ
    Toxicol Pathol; 2003; 31(5):554-61. PubMed ID: 14692624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single and repeated intravenous toxicity studies of pamiteplase (genetical recombination) in rats and monkeys.
    Ishikawa A; Ohata T; Imamura K; Iwasaki M; Sakai T; Matsuzawa T; Okazaki S
    J Toxicol Sci; 1997 May; 22(2):117-33. PubMed ID: 9198009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunopharmacology of recombinant human interleukin-18 in non-human primates.
    Herzyk DJ; Soos JM; Maier CC; Gore ER; Narayanan PK; Nadwodny KL; Liu S; Jonak ZL; Bugelski PJ
    Cytokine; 2002 Oct; 20(1):38-48. PubMed ID: 12441145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of recombinant human interleukin-6 on blood and immune parameters in middle-aged and old rhesus monkeys.
    Sun WH; Binkley N; Bidwell DW; Ershler WB
    Lymphokine Cytokine Res; 1993 Dec; 12(6):449-55. PubMed ID: 8123761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates.
    Bree AG; Schlerman FJ; Kaviani MD; Hastings RC; Hitz SL; Goldman SJ
    Biochem Biophys Res Commun; 1994 Nov; 204(3):1150-7. PubMed ID: 7980590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.
    Gilleece MH; Scarffe JH; Ghosh A; Heyworth CM; Bonnem E; Testa N; Stern P; Dexter TM
    Br J Cancer; 1992 Jul; 66(1):204-10. PubMed ID: 1637669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic, pharmacodynamic, and pharmacotoxic profiles of recombinant-methionyl human interleukin-2[alanine-125] (r-metHuIL-2[ala-125]) following intravenous and subcutaneous administration in rats.
    LeBel CP; Langlois L; Bell DP; Young JD; Kenney WC; Payne BJ; Sendelbach LE; Wong LC
    Hum Exp Toxicol; 1995 Nov; 14(11):909-15. PubMed ID: 8588953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and immunogenic behavior of three recombinant human GM-CSF-EPO hybrid proteins in cynomolgus monkeys.
    Coscarella A; Liddi R; Bach S; Zappitelli S; Urso R; Mele A; De Santis R
    Mol Biotechnol; 1998 Oct; 10(2):115-22. PubMed ID: 9819812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates.
    Gillio AP; Gasparetto C; Laver J; Abboud M; Bonilla MA; Garnick MB; O'Reilly RJ
    J Clin Invest; 1990 May; 85(5):1560-5. PubMed ID: 2332507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical safety of recombinant human thrombin.
    Heffernan JK; Ponce RA; Zuckerman LA; Volpone JP; Visich J; Giste EE; Jenkins N; Boster D; Pederson S; Knitter G; Palmer T; Wills M; Early RJ; Rogge MC
    Regul Toxicol Pharmacol; 2007 Feb; 47(1):48-58. PubMed ID: 16971028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety evaluation of recombinant human interleukin-4. I. Preclinical studies.
    Leach MW; Snyder EA; Sinha DP; Rosenblum IY
    Clin Immunol Immunopathol; 1997 Apr; 83(1):8-11. PubMed ID: 9073526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of the mono-PEGylated recombinant human interleukin-11 in cynomolgus monkeys.
    Yu KM; Lau JY; Fok M; Yeung YK; Fok SP; Zhang S; Ye P; Zhang K; Li X; Li J; Xu Q; Wong WT; Choo QL
    Toxicol Appl Pharmacol; 2018 Mar; 342():39-49. PubMed ID: 29407773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic proliferative changes and clinical signs in cynomolgus monkeys administered a recombinant derivative of human epidermal growth factor.
    Reindel JF; Gough AW; Pilcher GD; Bobrowski WF; Sobocinski GP; de la Iglesia FA
    Toxicol Pathol; 2001; 29(2):159-73. PubMed ID: 11421483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.